Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.
Latest SPAC News: NYSE president says IPO proceeds fall more than 90% while Nasdaq president remains hopeful for 2023, and Giuliani brothers sell pharma stocks as they invest in biotech SPACs
NYSE president says IPO proceeds fall more than 90%
Volatility and market uncertainty have taken a big hit on the number of companies going public, driving down initial public offering proceeds by 93% this year, Lynn Martin, president of the New York Stock Exchange said on Wednesday.
“There is a lot of uncertainty and there’s a lot of different forces that are impacting markets,” said Martin during an interview at the Reuters NEXT conference.
Last year was a record for IPOs at the NYSE, fueled in large part by the boom in special purpose acquisition companies, but that activity has slowed to a trickle as high inflation and rising interest rates have soured market sentiment and SPACs have drawn regulatory scrutiny.
READNasdaq CEO hopeful IPOs will pick up in 2023, calls for more crypto regulation
Adena Friedman, chief executive officer of Nasdaq Inc., said on Wednesday she expects a quiet first half of 2023 for initial public offerings as investors remain cautious, but is hopeful activity will pick up in the second half of the year.
There are currently about 200 companies in the pipeline for initial public offerings on the Nasdaq, which is below the range of the last few years of 250 to 300, Friedman said during an interview at the Reuters NEXT conference.
Last year was a banner year for IPOs at Nasdaq with over 750 new listings, fueled in large part by the boom in special purpose acquisition companies, but that activity has slowed to a trickle as high inflation and rising interest rates have soured market sentiment and SPACs have drawn regulatory scrutiny.
READBrothers Who Made Billions on US Pharma Firm Revamp Health Bets
The Giulianis are selling Royalty Pharma stock as they invest in other health-focused firms, including a SPAC that merged with biotech business ProKidney (Nasdaq: PROK).
The brothers have started cutting their roughly $2.4 billion stake in Royalty Pharma for the first time since its New York listing more than two years ago. Their investment funds have filed to sell up to almost $100 million of stock in the company, which buys pharmaceutical royalties, after offloading about $150 million — or roughly 6% of the holding — in recent months.
Germano, 50, and Giammaria, 44, have meanwhile made more than a dozen investments worldwide this year, mostly in health-related companies. They poured at least $22 million into a blank-check firm co-founded by Chamath Palihapitiya that merged in July with biotech business ProKidney Corp., as well as $16 million into biotech startup ReNAgade Therapeutics and nutrition company BioLumen.
Terms Tracker for the Week Ending July 11, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. One more IPO priced this week bringing July’s total to 8. However, there are still three more weeks left in the month so that number...
At the SPAC of Dawn Lately de-SPACs have been announcing corporate moves of a kind frequently in trios as was the case earlier this week when WeBull (NASDAQ:BULL), AST SpaceMobile (NASDAQ:ASTS) and Quantum-Si (NASDAQ:QSI) all announced major equity raises. This week, it is a trio of de-SPACs making reverse stock splits in unison, which is...
A look at Plus’ software-first approach to autonomous trucking. After years of investment and excitement, the dawn of self-driving cars and trucks is now here. The question now is which business model among autonomous driving technology companies will win out? This week, we speak with David Liu, CEO of autonomous trucking company Plus. Plus announced...
At the SPAC of Dawn One thing that SPAC investors can typically count on while their money is invested in a SPAC’s trust is that it is going to grow one way or the other between now and their next redemption opportunity, but the devil can occasionally be in the details. In 2024, it became...
Thunderstone has filed for a $50 million SPAC to put a new first-time Asia-based team in action on a generalist hunt. The new SPAC is offering investors a right to a 1/8 share in each unit with 18 months to initially complete a business combination. It is the 8th fresh S-1 filed with underwriter D....